NEW YORK CITY (dpa-AFX) - Bristol-Myers Squibb Company (BMY) announced the commercial launch of the ORENCIA ClickJect Autoinjector, a new self-administered autoinjector for adults with moderate to severe rheumatoid arthritis.
ORENCIA SC and IV is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. ORENCIA SC has not been studied in pediatric patients.
Copyright RTT News/dpa-AFX